UBS Group’s Longevity Health Holdings, Inc. Warrant XAGEW Stock Holding History

UBS Group’s Portfolio XAGEW Stock Details XAGEW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,399	Closed	-$42	–	11290
2025 Q2	$42	Sell	1,399 -11,287	-89%	-$367	﹤0.01%	10065
2025 Q1	$279	Buy	12,686 +12,570	+10,836%	+$434	﹤0.01%	9853
2024 Q4	$5	Sell	116 -8,860	-99%	-$517	﹤0.01%	9836
2024 Q3	$494	Buy	8,976 +8,845	+6,752%	+$738	﹤0.01%	8921
2024 Q2	$9	Buy	+131	New	+$13	﹤0.01%	9371
2023 Q4	–	Sell	-2,710	Closed	-$569	–	10034
2023 Q3	$569	Buy	+2,710	New	+$670	﹤0.01%	8401
2022 Q2	–	Sell	-250	Closed	–	–	11080
2022 Q1	$0	Buy	+250	New	+$190	﹤0.01%	11031

Other funds holding XAGEW

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

UBS Group's XAGEW Position: Q3 2025 in Review

UBS Group sold out of Longevity Health Holdings, Inc. Warrant (XAGEW) in Q3 2025, closing a stake of 1,399 shares — an estimated $42 sold.

UBS Group first reported a position in XAGEW in Q1 2022 and held it in 7 quarters. The position peaked at $569 in Q3 2023. 1 fund tracked by Wall St. Rank holds XAGEW as of Q3 2025.

UBS Group reported no remaining Longevity Health Holdings, Inc. Warrant position as of Q3 2025 after selling out during the quarter.
UBS Group sold 1,399 Longevity Health Holdings, Inc. Warrant shares in Q3 2025, an estimated $42.
UBS Group first reported a position in Longevity Health Holdings, Inc. Warrant in Q1 2022 and held it in 7 quarters.
UBS Group's Longevity Health Holdings, Inc. Warrant position peaked at $569 in Q3 2023.
1 fund tracked by Wall St. Rank held Longevity Health Holdings, Inc. Warrant as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.